Renflexis and Hyperhidrosis - a phase IV clinical study of FDA data

Summary:

Hyperhidrosis is reported as a side effect among people who take Renflexis (infliximab-abda), especially for people who are male, 30-39 old, have been taking the drug for < 1 month also take Gravol, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Hyperhidrosis when taking Renflexis. It is created by eHealthMe based on reports of 1,311 people who have side effects when taking Renflexis from the FDA, and is updated regularly.

What is Renflexis?

Renflexis has active ingredients of infliximab-abda. eHealthMe is studying from 1,316 Renflexis users. Check the latest studies of Renflexis.

What is Hyperhidrosis?

Hyperhidrosis (abnormally increased sweating) is found to be associated with 2,587 drugs and 3,521 conditions by eHealthMe. Check the latest studies of Hyperhidrosis.

On Dec, 19, 2025

1,311 people reported to have side effects when taking Renflexis.
Among them, 20 people (1.53%) have Hyperhidrosis.

Among these 20 people:

How long have people been on Renflexis when they have Hyperhidrosis? *

What is the gender of people who have Hyperhidrosis when taking Renflexis? *

female: 38.89 %
male: 61.11 %

What is the age of people who have Hyperhidrosis when taking Renflexis? *

What are other drugs people take besides Renflexis? *

What are other side effects people have besides Hyperhidrosis? *

Dyspnea (difficult or laboured breathing): 9 people, 45.00%
Nausea (feeling of having an urge to vomit): 8 people, 40.00%
Chest Pain: 7 people, 35.00%
Paleness (unusual lightness of skin colour): 7 people, 35.00%
Skin Blushing/flushing (a sudden reddening of the face, neck): 6 people, 30.00%
Hypotension (abnormally low blood pressure): 5 people, 25.00%
Dizziness: 5 people, 25.00%
Rashes (redness): 4 people, 20.00%
Nausea And Vomiting: 4 people, 20.00%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 15.00%

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 40.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 20.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 20.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 10.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 10.00%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 5.00%
Eosinophilic Esophagitis (Eosinophilic esophagitis (EoE) is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Renflexis and have Hyperhidrosis?

- Check whether Hyperhidrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Renflexis:

Renflexis (1,316 reports)

Hyperhidrosis treatments and more:

Hyperhidrosis (147,206 reports)

Browse all side effects of Renflexis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperhidrosis:

Hyperhidrosis (2,587 drugs)

Browse all the conditions that are associated with Hyperhidrosis:

Hyperhidrosis (3,521 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab-abda (the active ingredients of Renflexis) and Renflexis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.